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INTRODUCTION
Diabetic nephropathy (DN) is the leading cause of chronic kidney
failure. About 30-40% of patients with type 1 or type 2 diabetes
develop evidence of nephropathy, but recent reports indicate that
patients with type 2 diabetes can commonly progress to a signifi-
cant degree of renal impairment while remaining normoalbumin-
uric state (1, 2). In contrast, several biopsy studies have shown that
albuminuric patients with type 2 diabetes frequently suffer from
nondiabetic kidney disease (3-5), but the exact prevalence is not
known. Among the characteristic findings of DN, podocytes are
involved in the development of glomerular hypertrophy, podocy-
topenia, glomerulosclerosis, and foot process effacement (6). To-
gether with glomerular endothelial cells and glomerular basement
membrane, podocytes form the glomerular filtration barrier in the
kidney. Podocyturia may be an expression of glomerular disease
and is evaluated using urinary podocyte-specific molecules. Given
their dysregulation in kidney disease, podocytes and their specific
proteins and mRNA pose as attractive candidates as either diag-
nostic or predictor biomarkers of disease (7). Jim et al. investigated
the morphologic alterations of podocyte-specific proteins in dia-
betic nephropathy biopsies from patients with Type 2 diabetes
mellitus and found significant downregulation of synaptopodin, po-
docin and nephrin expression in the diabetic group as compared to
controls (8). Thus, determination of which markers are truly im-
portant for podocyte injuries due to diabetes mellitus in terms of
diagnosis, prognosis and therapy represents a critical issue.
Although microalbuminuria remains the gold standard for early
detection of DN, it is not a sufficiently accurate predictor of DN
risk. In addition, the gold standard procedure for diagnosis is a
kidney biopsy, but this procedure incurs a risk of bleeding com-
plications of variable severity, from transitory hematuria or as-
ymptomatic hematoma to life - threatening hemorrhage. From such
reasons, the diagnosis can be made in most cases without a kidney
biopsy. Exosomes are 40-100 nm membrane vesicles secreted into
the extracellular space by numerous cell types. These structures
can be isolated from body fluids including urine and plasma.
Exosomes were first discovered over 30 years ago and were consid-
ered to be little more than a means of cellular garbage disposal (9).
The most important biological function of exosomes is their possible
use as biomarkers in clinical diagnosis. Urinary exosomes are an
appealing source for biomarker discovery as they contain mo-
lecular constituents of their cell of origin, including proteins and
genetic materials, and they can be isolated in a non- invasive man-
ner. Urinary exosomes are secreted into the urine when a mul-
tivesicular body fuses with the membrane of cells from all nephron
segments. One of the first publications describing vesicles in the
urine dates back to 1987 when Wiggins et al. described the pres-
ence of exosomes in urine from nephrotoxic nephritis rabbit (10).
For DN, considerable advances have been achieved with biomarkers
derived from urinary exosomes. Accordingly, Wilm’s tumor-1
(WT1) protein expression appears to increase with the decline of
the renal function in DN (11). Interestingly, urinary WT1, most
likely derived from the podocyte, may thus qualify as a simple
marker of podocyte injury rather then a specific marker of DN
(12, 13). However, the detection of WT1 protein in western blot in
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these reports was ambiguous, because large amount of albumin in
loaded samples distorted the bands and there were no adequate
controls to exclude non-specific bands. Moreover, the direct useful-
ness of measuring WT1 proteins as biomarkers is hampered by diffi-
culty in reproducibility in terms of quantification. Interest in uri-
nary exosomes intensified after the discovery that they contain not
only protein but also mRNA and microRNA (miRNA) markers of
renal dysfunction and structural injury.
The Wilms’ tumor suppressor protein WT1 functions as a tran-
scriptional regulator of genes controlling growth, apoptosis, and
differentiation. WT1 has been shown to play crucial roles during
embryogenesis, in particular during kidney development. The per-
sistent expression of WT1 throughout life suggests that WT1
plays a role in the homeostasis of the mature podocyte (14). WT1
regulates the expression of many genes indispensable for podo-
cyte’s development or homeostasis, such as podocalyxin (15),
nephrin (16, 17), BMP7 and so on (18). WT1 mRNA expression was
reported in a temporal pattern that is restricted from embryo to
short after birth (19). WT1 null mice lack kidneys (20), and, when
engineered to express a human WT1 transgene, the animals sur-
vive but develop mesangial sclerosis (21), depending on the WT1
expression level. In this study, we evaluated the significance of
urinary exosomal WT1 as a non- invasive diagnostic and predictive
biomarker in patients with DN.
MATERIALS AND METHODS
Study design

Twenty patients with overt or heavy proteinuria due
to DN or minimal change nehrotic syndrome (MCNS), and 5
healthy subjects were enrolled in this study. DN and MCNS were
proven by renal biopsy. Type 2 diabetes mellitus was diagnosed
according to the Japan Diabetes Society criteria (22). All of the
procedures were performed in accordance with the guidelines of
the Helsinki Declaration on Human Experimentation and the
Ethical Guidelines on Clinical Research published by the Japanese
Health, Labour and Welfare Ministry. This study was approved by
the Ethics Committee of Tokushima University, and informed
written consent was obtained from all patients and healthy sub-
jects.
Laboratory examination

Creatinine in serum was measured by a
enzymatic method. Twenty four-hour urine protein in g/day was
determined to multiply the 24-hour urine volume by the urine
protein concentration measured using a pyrocatechol violet molyb-
date dye-binding method. Body mass index (BMI) was calculated
by dividing weight (in kg) by height squared (in m2).
Urine preparation and Isolation of Urinary Exosome

Urine sam-
ples (50-150 mL) were collected from healthy subjects and pa-
tients, (before biopsy in the case of patients) in sterile containers
and centrifuged at 3000 rpm fixed angle rotor for 10 min at room
temperature (within 1 hour of collection) to remove any particulate
matter including cells and cell debris. The clarified urine was
stored at -80 before further analysis. The supernatants were ul-
tracentrifuged for 1 h at 70,000 xg using an angle rotor (RP-65 ;
Hitachi Koki Co, Ltd.). The pellets were resuspended in 5 ml of
0.25 M sucrose, 20 mMHEPES-NaOH (pH 7.2) and pour carefully
on top of 30 ml sucrose density gradients (2-0.25 M sucrose, 20
mMHEPES-NaOH (pH 7.2)) in 40 PA centrifuge tube (329607A ;
Hitachi Koki Co, Ltd.). That sample were ultracentrifuged for 20 h at
100,000 xg using a swing rotor (RPS-28SA, Hitachi Koki Co, Ltd.)
and fractionated to 2 ml x 12 samples in 5 PA centrifuge tube
(332245A ; Hitachi Koki Co, Ltd.) by collecting from the bottom of
the tube. The fractions were diluted with 3 ml PBS, and ultra-
centrifuged for 1hr at 200,000 xg using a swing rotor (RPS-50-2 ;
Hitachi Koki Co, Ltd.). The pellets were resuspended in 50 μl PBS.
The recovery efficiency and purity were analyzed by silver staining
and western blot.
Western blot

Urinary proteins were resolved by SDS-PAGE ac-
cording to Laemmli method. Cultured cells were suspended in
RIPA buffer (50 mM Tris, pH 7.5, 150 mMNaCl, 1% Nonindet P-40,
0.25% SDS, 1 mM Na3VO4, 2 mM EDTA, 1 mM phenylmethylsul-
fonyl fluoride, 10 mg/ml of aprotinin), and incubated for 1 h at 4.
After centrifugation, the supernatants were used as total cell
lysates. After electrophoresis, the proteins were transferred onto a
nitrocellulose membrane (Hybond-ECL ; GE Healthcare) using
Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) at a constant
voltage of 10 volts for 30 min. Membrane were probed with the
following antibodies : mouse monoclonal anti -WT1 antibody,
Clone 6FH2 (Millipore, Billerica, MA) at a dilution of 1 : 500 ;
mouse monoclonal anti -α-tubulin antibody (Sigma-Aldrich) at 1 :
5000 ; rabbit polyclonal anti -WT1 antibody (Santa Cruz Biotech-
nology, CA) at 1 : 500 ; mouse polyclonal anti -CD63 antibody (Santa
Cruz Biotechnology, CA) at 1 : 1000 ; rabbit polyclonal anti -CD81
antibody (Cosmobio, Japan) at 1 : 1500 as a primary antibody, re-
spectively. ECL Western blotting detection system (GE Healthcare).
On the one hand, the gel was stained using the silver staining
method (Bio-Rad Silver Stain).
RT-PCR and Quantitative RT-PCR analysis
Purified human fetal kidney and adult kidney total RNA (25 μg)
were purchased from Agilent Technologies Inc. (Santa Clara, CA)
and diluted to 250 ng/μl. Total RNA was extracted from collected
exosomes and cultured podocytes using the TRIzol reagent
(Invitrogen). The RNA was reverse-transcribed with oligo(dT)
primer using a SuperScript first -strand synthesis kit (Invitrogen)
to generate the first -strand cDNA, followed by PCR to detect the
expression of podocyte-specific genes and GAPDH. The sequences
of the PCR primers were as follows : 5’ -GGACATAGTCTGC-
ACTGTCGAT-3’ and 5’ -GGCAAATCTGACAACAAGACG-3’ for
Nephrin ; 5’ -GTACGAGAGCGATAACCACACA-3’ and 5’ -GGC-
TTTTCACCTGTATGAGTCC-3’ for WT1 ; 5’ -AAAACCAAAGAA-
ACCACCACCT-3’ and 5’ -GGCATCTTTGGTCTATTTGCAG-3’ for
CD2AP ; 5’ -GCTACTACCGAATGGAAAATGC-3’ and 5’ -AGTTC-
TGTTGCTGGGAGAAGAC-3’ for Podocin ; 5’ -TGCACAAAATC-
AACAATGTGAA-3’ and 5’ -TTCTCGTAGTCCTCCATCAGGT-3’
for Actn4 and 5’ -TGCATGGCCGTTCTTAGTTGGT-3’ and 5’ -
CGCTACACTGACTGGCTCAGCG-3’ for Rn18s. The reaction
products were separated on 1.5% agarose gel and stained with
ethidium bromide. In quantitative RT-PCR analysis, amplification
was conducted in MiniOpticon real - time PCR detection system
(Bio Rad) using TaqMan gene expression assays (Applied Biosys-
tems, CA). The cycling parameters were 10 minutes at 95, followed
by 50 cycles of 15 sec at 95 and 60 sec at 60. Normalization was
performed using Rn18s as internal standards.
Histological Studies

Histopathological studies were performed
on human tissues. Kidney specimens (n = 20) were obtained from
renal biopsies. Kidney tissue blocks for light microscopy examina-
tion were fixed with Dubosq-Brazil’s solution and embedded in
paraffin. Cryopreserved kidney tissues were cut in 4-μm-thick
sections and fixed in acetone for 5 min. Multiple sections were
prepared and stained with periodic acid silver methenamine (PAM)
and periodic acid-Schiff’s reagent (PAS). Kidney sections were
treated as previously described (23, 24). For immunofulorescence,
cells were grown on type I collagen coated glass coverslips and
fixed using 4% paraformaldehyde in PB for 10 min. Subsequently,
cells were permeabilized with 0.1% Triton X. Sections were incu-
bated with the anti -WT1 (Santa Cruz, CA), and anti -Nephrin (IBL)
antibodies followed by incubation with the appropriate fluorescent
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secondary antibodies. All procedures were performed at room tem-
perature. Specimens were viewed with a confocal laser scanning
microscopy (LEICA, Wetzlar, Germany).
Cell culture

Conditionally immortalized murine podocytes were
purchased from Cell Lines Service (CLS, Eppelheim, Germany)
(25). Podocytes were grown in RPMI 1640 medium (Gibco,
Invitrogen, Carlsbad, CA, USA) containing 4 mM glutamine, 5%
exosome-free fetal bovine serum (FBS) and 100 units/ml peni-
cillin/streptomycin. Podocytes between passage 5 and 10 were
cultured on the plates. The cells were passaged routinely at 80%
confluence by using Accutase (Millipore, Billerica, MA). Condi-
tionally immortalized podocytes were propagated under permis-
sive condition at 33 as previously described (25). To induce
differentiation, cells were switched to 37 (nonpermissive condi-
tion). The subconﬂuent cell monolayers were cultured in serum-
deprived media containing 5 mM D-glucose and 0.5% FBS for 24 h
and then divided into three experimental groups according to glu-
cose concentration. The normal glucose (NG) group comprised
conﬂuent cell monolayers cultured with 5 mM D-glucose, the high
glucose (HG) group was cultured in 30 mM D-glucose and the
osmotic control (OC) group was cultured in 30 mM D-mannitol.
Conﬂuent cells were taken at 24 h after stimulation and used for
the extraction of protein. Cell nuclear and cytoplasmic fractions
were prepared using a nuclear/cytosol fractionation kit of Biovision
Inc. (Mountain View, CA, USA) according to the manufacture’s di-
rection.
Statistical analysis
For analysis of differences between patients with DN and MCNS,
the Mann Whitney U test for non-normally distributed data. The
area beneath the receiver operating characteristic (ROC) curves
was used to show the power of a biomarker in diagnosis of DN.
Specificity, sensitivity were calculated. Statistical significance was
accepted as p0.001 in all tests.
RESULTS
Exosomes Are Present in Human Urine
Isolation of exosomes from cell culture media and body fluids is
presently a tedious, non-specific, and difficult process. The widely
used approach is based on ultracentrifugation in combination with
sucrose density gradients or sucrose cushions to float the relatively
low-density exosomes away from other vesicles and particles (26).
Exosomes settle at the density of 1.13 to 1.19 g/ml as can be seen in
Figure 1A that shows a silver staining of fractions following sucrose
density gradient centrifugation of exosomes. Samples were next
analyzed by Western blots with antibodies specific to CD63 and
CD81 (Fig. 1B, C), well characterized exosomal markers (26, 27).
We picked fractions 5 and 6 that correspond to the density of
exosomes and also showed highest enrichment of proteins and the
surface molecules CD63 and CD81.
Podocyte-derived signal transduction factors Are Present in
Urine from Patients with CKD
There is a database of urinary exosome proteins is based on
published protein mass spectrometry data from the NHLBI Epithe-
lial Systems Biology Laboratory (ESBL). The set of identified
podocyte vesicle proteins was compared to protein sets extracted
from ExoCarta (http : //exocarta.ludwig.edu.au/, April 2011 ver-
sion), a database specially dedicated to exosomes from various
species and their components (28). According to the ExoCarta
database, 6 podocyte-derived signal transduction factors (PDSTFs)
have been identified in human exosomes isolated from human
urine. All data are from urinary exosomes isolated from patients
with DN or MCNS and healthy human volunteers (29, 30). First, we
examined whether PDSTFs and aquaporin-2 (AQP2) is expressed
in the exosomes from 3 groups : patients with DN, patients with
MCNS and healthy subjects. The water channel AQP2 is one
biomarker that can be readily measured in urine (31). Excretion of
AQP2 in urinary exosome was reported to be detected from healthy
subjects who had no evidence of recent kidney or urinary tract
disease (32). Among PDSTFs in exosome, CD2AP was expressed
in all groups as well as AQP2 (Fig. 2A). Next, we investigated
whether PDSTFs show significant difference between patients
with DN and MCNS. Out of 6 molecules of PDSTF, the WT1
mRNA in urinary exosomes was positive by RT-PCR method
only in the patients with DN (Fig. 2B).
Glomerular immunoreactivity for WT1 in patients with DN or
MCNS

We investigated the association between glomerular ex-
pression of WT1 and podocyte injuries in patients with DN and
patients with MCNS. Reduction of glomerular immunoreactivity
for WT1 was correlated with the severity of sclerotic lesions in dia-
betic renal glomeruli, as previously reported (33) (Fig. 3). On the
Figure 1. Isolation and fractionation of urinary exosome on a sucrose
gradient density.
Exosome pretreated with lysis buffer was loaded on a sucrose density
gradient prepared by layering 12 sucrose solutions of concentrations.
The gradients were removed from the top and the density of each fraction
(lane 1 to 12) was calculated by weighing a fixed volume of each frac-
tion. The fractions were analyzed by silver staining (A), western blot
analysis for CD63 (B), and CD81 (C) in exosome. The results are repre-
sentative of at least five independent experiments. M ; molecular size
marker.
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other hand, the reduction in number of WT1-positive podocytes
was not observed in patients with MCNS. Moreover, because
nephrin gene expression is transcriptionally activated by WT1
(34), glomerular Nephrin expression was reduced in parallel
with WT1 expression in patients with DN (Fig. 3). These histo-
logical observations suggest that the expression levels of WT1 is
not associated with the severity of proteinuria.
Cultured Podocyte-derived WT1 in exosome in high glucose
stimulation
To elucidate the mechanisms of exosome secretion from podo-
cyte, we examined the expression of WT1 in cultured podocytes
with high glucose stimulation. The expression of WT1 was de-
creased in podocytes treated with high glucose. Similarly, mannitol
stimulation as an osmotic control presented a slightly decreased
expression of WT1 protein (Fig. 4A). In the steady state, WT1
regulates nephrin transcription as a nuclear transcriptional factor
through binding to the promotor region of nephrin (35). Next, we
examined the distribution of WT1 protein in podocytes treated with
Figure 2. Expression of PDSTFs mRNA in urinary exosomes.
(A) RT-PCR analysis of podocyte marker genes for mRNA obtained from
urinary exosomes in pooled urine collected from patients with DN and
MCNS, and healthy subjects. (B) RT-PCR analysis of positive podocyte
marker genes for mRNA obtained from urinary exosomes in representa-
tive patients with DN and MCNS.
Figure 3. Light Micrograph and Glomerular expression of WT1 in
patients with DN and MCNS.
Representative photomicrographs of periodic acid -Schiff methenamine
(PASM), periodic acid -Schiff staining (PAS), and immunohistochemical
staining of WT1 and Nephrin are shown (original magnification x 400).
The left panels are data from patients with DN, and the right panels are
from patients with MCNS.
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high glucose. High glucose stimulation significantly induced cyto-
plasmic translocation of WT1. This phenomenon was not observed in
podocytes treated with mannitol (Fig. 4B). Cytoplasmic transloca-
tion of WT1 may be followed by release extracellularly. Actually we
confirmed that conditioned media from cultured podocytes ex-
posed high glucose release exosomes (Fig. 4C). However, we
could not detect WT1 protein in the exosomes obtained from cul-
tured media. This is probably due to the relatively low amount of
exosomal WT1 protein and due to the threshold of western blot. To
cope with this problem, we performed RT-PCR analyses, indicat-
ing WT1 mRNA was contained the exosomes from cultured media
(Fig. 4D). Thus, high glucose stimulation significantly affected ho-
meostatic balance in podocyte, resulting in cytoplasmic transloca-
tion of WT1 and release exosome containing both WT1 protein and
mRNA.
Patients’ demographic and clinical characteristics and evalu-
ation for CKD patients
Baseline characteristics of patients with MCNS or DN are
shown in Table 1. Average age at biopsy was 44.816.6 years, and
mean follow-up time after renal biopsy was 57.2 months (range : 7-
98 months). Although patients with DN were older, had higher
SBP and DBP, There was no significant difference in proteinuria
levels and renal function, that is, serum creatinine levels or eGFR
values between the two groups. Urinary exosomal WT1 mRNA
were significantly increased in the patients with DN compared with
patients with MCNS and control subjects (Fig. 5A). Next, receiver
operating characteristic (ROC) curve analysis was performed to
examine whether urinary exosomal WT1 mRNA could be used as a
diagnostic biomarker for patient with DN. It showed an area under
the ROC curve (AUC) of 0.705 (Fig. 5B). The result indicated that
urinary exosomal WT1 mRNAmight be a good candidate biomarker
to diagnose DN. Next, the elevated value of urinary exosomal WT1
mRNA on rapid decline in kidney function was examined in our
patients. During the follow-up period, 15.0% (3/20) patients with
DN developed end-stage renal disease (ESRD) (Fig. 5C). On the
other hand, no patients with MCNS developed ESRD. The rate of
progression to ESRD was lower in the patients with low urinary
exosomal WT1 mRNA (0% vs. 15%, P = 0.049). In conclusion, pa-
tients with DN whose WT1 mRNA values high developed rapid
decline ineGFR.
DISCUSSION
Diabetes mellitus is a chronic disease that affects 366 million
people worldwide (6.4% of the adult population) and is expected to
rise to 552 million by 2030 (36). This is a clinical syndrome character-
ized by persistent albuminuria (300 mg/24 h, or300 mg/g
creatinine), a relentless decline in glomerular filtration rate (GFR),
raised arterial blood pressure, and enhanced cardiovascular mor-
bidity and mortality. Although microalbuminuria is a widely used
indicator for DN, its diagnostic accuracy is limited by the fact that
structural damage might precede albumin excretion (37). In addi-
tion, microalbuminuria is not specific for the presence of DN
alone as non-diabetic patients with progressive chronic kidney dis-
ease may also develop microalbuminuria (38). At present, the most
reliable diagnostic method is the renal biopsy to diagnose DN,
but it is impossible to perform biopsies for all cases due to its inva-
siveness. Therefore, sensitive and specific biomarkers that can pre-
dict patient’s susceptibility to DN are needed (39). Increasing evi-
dence suggests that these glomerulopathies are frequently caused
by primary lesions in the renal podocytes. Among the characteristic
findings of diabetic nephropathy, podocytes are involved in the de-
velopment of glomerular hypertrophy, podocytopenia, glomerulo-
sclerosis, and foot process effacement (40). Podocyturia is well de-
scribed in many glomerular diseases including DN (41, 42). How-
ever, the number of podocyte in urine is a result of podocyte
Figure 4. WT1 in exosome in media from cultured podocytes expo-
sured with high glucose or mannitol.
(A) WT1 protein in mouse podocytes cultured in exosome- free medium
containing normal glucose (CTL, 5.5 mM), high glucose (HG, 30
mM) or D-mannitol (30 mM) (OC) for 24 h was monitored by western
blot. Counter stained with coomassie blue was shown in order to visualize
total protein and thus confirm equal sample loading. WC ; whole cell
lysate. (B) Western blot analysis for WT1 of nuclear (Nu) and cytoplasmic
(Cyto) fraction and the loading controls histone H3 and α - tubulin. (C)
Western blot analysis for CD63 and CD81 as exosome markers for
exosomes obtained from conditioned media (mExo) for cultured podo-
cytes. (D) RT-PCR analysis for WT1 mRNA obtained from exosome in
cultured media. Rn18 gene was used as internal control. The results are
representative of at least three independent experiments.
Table 1. Demographic and clinical characteristics of patients with
DN or MCNS
DN (n=10) MCNS (n=10) p value
Age, y 57.06.2 32.815.1 0.001
Weight, kg 64.98.0 65.014.3 0.837
Height, cm 166.28.8 162.99.4 0.681
BMI, kg m-2 23.83.6 23.64.1 0.931
SBP, mmHg 143.016.7 112.210.0 0.001
DBP, mmHg 80.45.8 65.47.1 0.001
Cr, mg/dL 1.40.8 0.80.2 0.099
eGFR 52.827.3 92.720.1 0.006
BUN, mg/dL 20.610.3 11.44 0.059
UA, mg/dL 5.61.4 6.51.8 0.714
u-prot, mg/dL 249.6183.0 736.1793.5 0.340
u-Cr, mg/dL 56.922.8 161.6108.8 0.001
PCR 5.03.5 4.22.6 0.667
All values given as mean (standard deviation) ; BMI=body mass index ;
SBP=systolic blood pressure ; DBP=diastolic blood pressure ; PCR=
protein -creatinine ratio ; n=sample size
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depletion and do not show the states of podocyte injuries prior to
podocyte loss. Therefore, it is strongly anticipated that some urinary
biomarkers can provide us information on kidney disease status.
Exosomes are small vesicles containing unique RNA and protein
cargo, secreted by all cell types in culture. Urine is emerging as a
biological fluid suitable to perform liquid biopsy in a minimally inva-
sive manner. It is believed that urine is an ideal specimen for
finding potential biomarkers of kidney diseases due to easy accessi-
bility and can directly reflect the real - time status of the kidney in-
flammation and tissue damage. The difficulty, however, associated
with urine is that their exosomal concentration and overall composi-
tion varies largely depending on the urine volume and food uptake
while the blood volume remain constant. Quite a lot of differentially
expressed proteins identified by mass spectrometry in the exoso-
mal proteome could not be verified by western blot analysis (43).
This might be due to the relatively low amount of exosomal pro-
tein in the urine while the detection threshold of western blotting
might not be sensitive enough for the identification of individual
proteins. Given these issues, measurement the amount of mRNA in
exosome form urine sample is useful in terms of quantification. In
addition, exosomes isolated by ultracentrifugation alone contain
both exosomes and aggregated protein and cell free nucleic acid
contaminants. Therefore, we carried out sucrose gradient centrifu-
gation in this study. As a result, we could effectively separates
exosomes and other extracellular vesicles from these contami-
nants.
In this study, we characterized the association between urinary
exosomal biomarkers and kidney function in patients with DN or
MCNS. Although five biomarkers, WT1, podocin, Actn4, CD2AP,
and Nephrin, which are all correlated with podocyte homeostasis,
only urinary exosomal WT1 mRNA levels could differentiate DN
from MCNS in RT-PCR assay. Subsequent analysis using qPCR
revealed that not only patients with MCNS but control subjects
exhibits a slight amount of urinary exosomal WT1 mRNA in their
urine. From these facts, it is considered that podocytes may secrete
exosomal WT1 mRNA even in the physiological steady state. More
importantly, prolonged hyperglycemia will gradually cause signifi-
cant damage on podocytes in the patients with diabetes mellitus,
resulting in podocyte loss. Compared with patients with MCNS,
even though the level of albuminuria was about the same, patients
with DN exhibited eminent exosomal WT1 excretion in urine. In
this process, high amount of urinary exosomal WT1 mRNA was
observed and associated with future decline in eGFR. So far exten-
sive evidence has accumulated to suggest that WT1 acts as a com-
plex multifunctional nuclear protein involved in at least two levels of
gene expression control : transcription and RNA processing (44,
45). Thus, the relation between WT1 and eGFR decline goes be-
yond reflecting overall worse clinical status and CVD outcomes.
In vitro, western blot analyses revealed that WT1 protein par-
tially translocated to cytoplasm from nucleus under high glucose
stimulation. Moreover, exosomes extracted from media of cul-
tured podocyte with treated high glucose exhibited WT1 mRNA
expression. Exosomes are homogenous small particles ranging
from 40 to 100 nm in size and are derived from the endocytic
recycling pathway. In endocytosis, endosomes where intraluminal
vesicles bud off into an intra-cytoplasmic lumen directly fuse with
the plasma membrane and release exosomes into the extracellular
space (46), instead of fusing with the lysosome. This cytoplasmic
translocation of WT1 may be followed by the secretion of exosome
from podocytes.
In conclusion, our study has shown that urinary exosomal WT
mRNA, especially in patients with DN, can be a non- invasive bio-
marker predicting future decline in renal function. More valuable is
that high level of urinary exosomal WT mRNA separates patients
with DN from those with MCNS. Due to the limitation of patients
from one institute, further validation in prospective cohorts from
areas and races is needed.
CONCLUSIONS
Urinary exosomes are microvesicles released by podocytes con-
taining information of the originated cells. PDSTFs are good candi-
dates to assess podocyte injuries. The profile of PDSTFs in urinary
exosomes from patients with DN is different from that from pa-
tients with MCNS. Among PDSTFs in urinary exosomes, WT1
mRNA levels reflected damage of diabetic glomeruli in the pa-
tients. Urinary exosomal WT1 mRNA can predict the decline in
eGFR for the following several years in patients with DN.
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Figure 5. Expression levels of WT1 and changes in eGFR after the
measurement of WT1.
(A) Expression of urinary exosomal WT1 mRNA from patients with
DN or MCNS and healthy subjects determined by qPCR. (B) ROC curve
analyses of urinary exosomal WT1 mRNA for diagnosis of DN. (C)
Rate of change in eGFR after the measurement of urinary exosomal
WT1 mRNA levels in the patients with DN (red circle) and MCNS (blue
circle).
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